Pfizer’s Ibrance gets new indication

SILVER SPRING, Md. — The Food and Drug Administration on Friday approved a new indication for Pfizer’s Ibrance (palbociclib). The treatment for metastatic breast cancer is now approved for hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer in combination with fulvestrant for patients whose cancer progresses after endocrine therapy. 

 

“Today's news gives more women with metastatic breast cancer the opportunity to benefit from this first-in-class medicine," Pfizer Oncology president and general manager Liz Barrett said. “The expanded approval of Ibrance is supported by a robust body of evidence and underscores Pfizer's continued commitment to addressing the needs of the metastatic breast cancer community.”